IL161716A0 - ADENOSINE A2a RECEPTOR ANTAGONISTS - Google Patents

ADENOSINE A2a RECEPTOR ANTAGONISTS

Info

Publication number
IL161716A0
IL161716A0 IL16171602A IL16171602A IL161716A0 IL 161716 A0 IL161716 A0 IL 161716A0 IL 16171602 A IL16171602 A IL 16171602A IL 16171602 A IL16171602 A IL 16171602A IL 161716 A0 IL161716 A0 IL 161716A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
IL16171602A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL161716A0 publication Critical patent/IL161716A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL16171602A 2001-11-30 2002-11-26 ADENOSINE A2a RECEPTOR ANTAGONISTS IL161716A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30
PCT/US2002/037710 WO2003048165A1 (en) 2001-11-30 2002-11-26 ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
IL161716A0 true IL161716A0 (en) 2004-09-27

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16171602A IL161716A0 (en) 2001-11-30 2002-11-26 ADENOSINE A2a RECEPTOR ANTAGONISTS

Country Status (19)

Country Link
US (1) US6916811B2 (pt)
EP (1) EP1448565B1 (pt)
JP (2) JP4284182B2 (pt)
KR (1) KR20050044593A (pt)
CN (1) CN1692116A (pt)
AR (1) AR037680A1 (pt)
AT (1) ATE453647T1 (pt)
AU (1) AU2002346503A1 (pt)
CA (1) CA2468649C (pt)
DE (1) DE60234951D1 (pt)
ES (1) ES2336435T3 (pt)
HK (1) HK1063780A1 (pt)
HU (1) HUP0402018A3 (pt)
IL (1) IL161716A0 (pt)
MX (1) MXPA04005209A (pt)
PE (1) PE20030665A1 (pt)
TW (1) TW200306837A (pt)
WO (1) WO2003048165A1 (pt)
ZA (1) ZA200404161B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237576T3 (es) * 2000-05-26 2005-08-01 Schering Corporation Antagonistas del receptor a2a de adenosina.
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
PE20030477A1 (es) 2001-10-15 2003-06-06 Schering Corp ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
AU2003245380A1 (en) * 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
ES2354875T3 (es) 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
US7816353B2 (en) * 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
PL1678182T3 (pl) * 2003-10-28 2007-05-31 Schering Corp Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn
CN100528162C (zh) * 2003-12-19 2009-08-19 先灵公司 药物组合物
US7851478B2 (en) * 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
EA202191498A1 (ru) 2018-11-30 2021-08-20 Мерк Шарп энд Доум Корп. 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
CN114667287A (zh) * 2019-07-17 2022-06-24 泰昂治疗公司 腺苷a2a受体拮抗剂及其用途
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
CA2144330A1 (en) 1993-07-27 1995-02-09 Fumio Suzuki A therapeutic agent for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
ES2237576T3 (es) 2000-05-26 2005-08-01 Schering Corporation Antagonistas del receptor a2a de adenosina.
AU2003245380A1 (en) * 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
TWI375677B (en) * 2003-04-23 2012-11-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
ES2336435T3 (es) 2010-04-13
AU2002346503A1 (en) 2003-06-17
HK1063780A1 (en) 2005-01-14
US6916811B2 (en) 2005-07-12
CA2468649A1 (en) 2003-06-12
JP4284182B2 (ja) 2009-06-24
ATE453647T1 (de) 2010-01-15
ZA200404161B (en) 2005-11-30
AR037680A1 (es) 2004-12-01
EP1448565B1 (en) 2009-12-30
CN1692116A (zh) 2005-11-02
PE20030665A1 (es) 2003-08-08
JP2005511699A (ja) 2005-04-28
WO2003048165A1 (en) 2003-06-12
KR20050044593A (ko) 2005-05-12
EP1448565A1 (en) 2004-08-25
CA2468649C (en) 2009-03-10
HUP0402018A3 (en) 2008-06-30
HUP0402018A2 (hu) 2005-02-28
JP2008260776A (ja) 2008-10-30
TW200306837A (en) 2003-12-01
MXPA04005209A (es) 2004-08-19
US20030212059A1 (en) 2003-11-13
DE60234951D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
AU6808901A (en) Adenosine a2a receptor antagonists
IL161572A0 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL175759A0 (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
EP1636229A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
PL373953A1 (en) 7-amino-benzothiazole derivatives as adenosine receptor ligands
SI1622912T1 (sl) 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti
HK1059927A1 (en) Condensed purine derivatives as a1 adenosine receptor antagonists
NO20020979D0 (no) Selektive A2B-adenosin reseptorantagonister
IL162444A0 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU2002359524A8 (en) P2x7 receptor antagonists
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
IL158063A0 (en) Crf receptor antagonists
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
AU2002320199A1 (en) Purine derivatives as a2b adenosine receptor antagonists
GB0125183D0 (en) Receptor
GB0114929D0 (en) Receptor
GB0111959D0 (en) Receptor
GB0110662D0 (en) Receptor